We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Clinical Chemistry Analyzer Processes 300 Tests per Hour

By Labmedica staff writers
Posted on 04 Aug 2008
A clinical chemistry analyzer has been launched for low- to medium-volume laboratories with throughput needs of up to 300 tests per hour.

Compact and reliable, the cobas c 311 analyzer is suitable for satellite, STAT, and smaller hospital laboratories. More...
It offers a comprehensive clinical chemistry menu of more than 100 assays. Up to 45 assays can be performed simultaneously. High onboard reagent stabilities and lot-to-lot calibration optimize reagent usage makes the analyzer cost-effective and convenient to use.

All reagents in the ergonomic cobas c packs are liquid and ready-to-use, and all components of a parameter are integrated into a single cassette. The integration of cobas e-services for electronic updates and downloads makes handling of application, calibrator, and control information seamless and precise. Special features of the 311 analyzer include intelligent clot detection, carryover-free ultrasonic mixing, and test-specific serum indices.

Introduced by Roche (Basel, Switzerland), the cobas c 311 analyzer represents the latest collaboration between the company and its strategic partner, Hitachi High Technologies (Tokyo, Japan). The analyzer was launched prior to the American Association of Clinical Chemistry (AACC) Congress, which was held on July 29-31, 3008, in Washington DC (USA). Dirk Ehlers, head of Roche professional diagnostics said, "The system will enable us to offer smaller laboratories many of the efficiencies and conveniences currently provided by the cobas 6000 analyzer series.”

The cobas c 311 analyzer complements the cobas 411 immunoanalyzer, which was released in December 2006. The two systems compose the cobas 4000 analyzer series, an efficient serum work-area solution designed to process more than 95% of the combined testing needs of low- to mid-volume laboratories.

Roche, a biotech company, is an innovator of products and services for the early detection, prevention, diagnosis, and treatment of diseases. Roche is a world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders, and diseases of the central nervous system.


Related Links:
Roche
Hitachi High Technologies

Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.